{"id":"everolimus-tablets","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Stomatitis/mouth ulcers"},{"rate":"30-40","effect":"Infections"},{"rate":"25-35","effect":"Rash"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"20-25","effect":"Fatigue"},{"rate":"15-25","effect":"Anemia"},{"rate":"15-20","effect":"Hyperglycemia"},{"rate":"15-20","effect":"Hyperlipidemia"},{"rate":"1-5","effect":"Pneumonitis"}]},"_chembl":{"chemblId":"CHEMBL1908360","moleculeType":"Small molecule","molecularWeight":"958.24"},"_dailymed":{"setId":"c7bb6ba1-9a7f-43f5-b058-ef26d4b59221","title":"EVEROLIMUS (EVEROLIMUS TABLETS) TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Everolimus is an mTOR inhibitor that suppresses cell cycle progression and angiogenesis by blocking the mTORC1 signaling pathway. This leads to reduced cell proliferation and increased apoptosis in cancer cells. It is also used as an immunosuppressant to prevent organ rejection by inhibiting T-cell activation.","oneSentence":"Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:50.184Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced renal cell carcinoma"},{"name":"Breast cancer (hormone receptor-positive, HER2-negative)"},{"name":"Pancreatic neuroendocrine tumors"},{"name":"Subependymal giant cell astrocytoma (SEGA)"},{"name":"Organ transplant rejection prevention"}]},"trialDetails":[{"nctId":"NCT06943755","phase":"PHASE2, PHASE3","title":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Exelixis","startDate":"2025-07-21","conditions":"Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)","enrollment":440},{"nctId":"NCT06428396","phase":"PHASE2","title":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-27","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT05153668","phase":"EARLY_PHASE1","title":"Everolimus Trial in Laryngotracheal Stenosis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-09-30","conditions":"Idiopathic Subglottic Tracheal Stenosis","enrollment":8},{"nctId":"NCT07435584","phase":"PHASE1, PHASE2","title":"Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"Colorectal Cancer","enrollment":38},{"nctId":"NCT05487859","phase":"PHASE2","title":"Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2025-12-31","conditions":"Kidney Cancer","enrollment":""},{"nctId":"NCT06105632","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-09","conditions":"Advanced or Metastatic Breast Cancer","enrollment":333},{"nctId":"NCT05949658","phase":"PHASE1","title":"Rapalog Pharmacology (RAP PAC) Study","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2024-05-15","conditions":"Aging","enrollment":72},{"nctId":"NCT05476939","phase":"PHASE3","title":"Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2022-09-29","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered","enrollment":433},{"nctId":"NCT02962414","phase":"PHASE3","title":"Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-08","conditions":"Tuberous Sclerosis Complex","enrollment":206},{"nctId":"NCT05252585","phase":"PHASE4","title":"A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-01","conditions":"Renal Angiomyolipoma","enrollment":4},{"nctId":"NCT06727305","phase":"PHASE1, PHASE2","title":"MTOR Inhibitors in Older Adults","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02","conditions":"Aging","enrollment":60},{"nctId":"NCT07024173","phase":"PHASE3","title":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2025-07-23","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":240},{"nctId":"NCT05933395","phase":"PHASE2","title":"Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2024-09-23","conditions":"Advanced Breast Cancer","enrollment":135},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT07002177","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","status":"RECRUITING","sponsor":"Forward Pharmaceuticals Co., Ltd.","startDate":"2025-06-01","conditions":"Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II","enrollment":196},{"nctId":"NCT07062965","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-05","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT03284957","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-20","conditions":"Breast Cancer","enrollment":136},{"nctId":"NCT01797523","phase":"PHASE2","title":"A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-10-07","conditions":"Endometrial Cancer","enrollment":62},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT07218575","phase":"PHASE2, PHASE3","title":"Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations","status":"NOT_YET_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-04","conditions":"Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease","enrollment":60},{"nctId":"NCT05501769","phase":"PHASE1","title":"ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer","status":"COMPLETED","sponsor":"Arvinas Estrogen Receptor, Inc.","startDate":"2022-09-08","conditions":"Breast Cancer","enrollment":32},{"nctId":"NCT06680921","phase":"PHASE3","title":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2024-11-14","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":460},{"nctId":"NCT07173556","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09","conditions":"Advanced Breast Cancer","enrollment":96},{"nctId":"NCT07165418","phase":"PHASE3","title":"A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-09-25","conditions":"Renal Cell Carcinoma (RCC)","enrollment":116},{"nctId":"NCT01734512","phase":"PHASE2","title":"PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-12-13","conditions":"Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas","enrollment":65},{"nctId":"NCT02123823","phase":"PHASE1","title":"BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-05-15","conditions":"Neoplasms","enrollment":164},{"nctId":"NCT01805271","phase":"PHASE3","title":"Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-03","conditions":"Primary Non-metastatic Breast Cancer, Who Remain Disease-free","enrollment":1278},{"nctId":"NCT00942734","phase":"PHASE2","title":"Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-07","conditions":"Head And Neck Cancer","enrollment":49},{"nctId":"NCT04195750","phase":"PHASE3","title":"A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-27","conditions":"Carcinoma, Renal Cell","enrollment":755},{"nctId":"NCT06942156","phase":"PHASE4","title":"Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-08-14","conditions":"Heart Transplant","enrollment":140},{"nctId":"NCT03173560","phase":"PHASE2","title":"Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-08-17","conditions":"Renal Cell Carcinoma","enrollment":343},{"nctId":"NCT03659136","phase":"PHASE2","title":"The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-11-28","conditions":"Breast Neoplasms","enrollment":103},{"nctId":"NCT02991807","phase":"PHASE1, PHASE2","title":"RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2017-06-12","conditions":"PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome","enrollment":46},{"nctId":"NCT02216786","phase":"PHASE2","title":"A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-01-16","conditions":"Estrogen Receptor Positive Breast Cancer","enrollment":333},{"nctId":"NCT03048825","phase":"PHASE3","title":"Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2018-02-01","conditions":"ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction","enrollment":7264},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT03154281","phase":"PHASE1","title":"Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast","status":"COMPLETED","sponsor":"Avera McKennan Hospital & University Health Center","startDate":"2017-07-26","conditions":"Breast Cancer, Ovarian Cancer","enrollment":14},{"nctId":"NCT03312738","phase":"PHASE2","title":"A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-15","conditions":"Advanced Breast Cancer","enrollment":159},{"nctId":"NCT02258451","phase":"PHASE2","title":"Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-04","conditions":"Breast Neoplasms","enrollment":283},{"nctId":"NCT02599324","phase":"PHASE1, PHASE2","title":"Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2015-12-01","conditions":"Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma","enrollment":263},{"nctId":"NCT03386539","phase":"PHASE3","title":"Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score","status":"UNKNOWN","sponsor":"Boston Children's Hospital","startDate":"2018-01-29","conditions":"Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases","enrollment":211},{"nctId":"NCT00934895","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2009-07-15","conditions":"Breast Cancer","enrollment":27},{"nctId":"NCT03245151","phase":"PHASE1, PHASE2","title":"Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-11-16","conditions":"Recurrent and Refractory Solid Tumors","enrollment":64},{"nctId":"NCT01698918","phase":"PHASE2","title":"Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-07","conditions":"Hormone Receptor Positive Breast Cancer","enrollment":202},{"nctId":"NCT03458221","phase":"PHASE2, PHASE3","title":"Signal TrAnsduction Pathway Activity Analysis in OVarian cancER","status":"RECRUITING","sponsor":"Gynaecologisch Oncologisch Centrum Zuid","startDate":"2023-01-31","conditions":"Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation, Therapy-Associated Cancer","enrollment":148},{"nctId":"NCT02049957","phase":"PHASE2","title":"Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Calithera Biosciences, Inc","startDate":"2014-02-13","conditions":"Breast Cancer","enrollment":118},{"nctId":"NCT02913261","phase":"PHASE3","title":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-03-10","conditions":"Corticosteroid Refractory Acute Graft vs Host Disease","enrollment":310},{"nctId":"NCT02915783","phase":"PHASE2","title":"A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-02-20","conditions":"Non Clear Cell Renal Cell Carcinoma (nccRCC)","enrollment":41},{"nctId":"NCT03355794","phase":"PHASE1","title":"A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2017-11-14","conditions":"Diffuse Intrinsic Pontine Glioma, Malignant Glioma of Brain, High Grade Glioma","enrollment":19},{"nctId":"NCT02539459","phase":"PHASE2","title":"Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2015-09-23","conditions":"Sporadic Angiomyolipomas (AMLs)","enrollment":20},{"nctId":"NCT00805129","phase":"PHASE2","title":"Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-12-05","conditions":"Bladder Cancer, Metastatic Transitional Cell Carcinoma","enrollment":46},{"nctId":"NCT03163667","phase":"PHASE2","title":"CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"Calithera Biosciences, Inc","startDate":"2017-09-06","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":69},{"nctId":"NCT01668784","phase":"PHASE3","title":"Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-10-09","conditions":"Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma","enrollment":821},{"nctId":"NCT05490095","phase":"PHASE1","title":"Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults","status":"COMPLETED","sponsor":"Sovargen","startDate":"2021-07-23","conditions":"Pharmacokinetics","enrollment":26},{"nctId":"NCT05189717","phase":"PHASE1","title":"A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults","status":"UNKNOWN","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2022-02-17","conditions":"Metastatic or Local Advanced Breast Cancer of Patients","enrollment":156},{"nctId":"NCT01529554","phase":"PHASE1, PHASE2","title":"Controlled Level EVERolimus in Acute Coronary Syndromes","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2015-01-08","conditions":"Acute Coronary Syndromes","enrollment":150},{"nctId":"NCT01263951","phase":"PHASE2","title":"Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone","status":"UNKNOWN","sponsor":"Thomas Jefferson University","startDate":"2010-11","conditions":"Differentiated Thyroid Cancer","enrollment":35},{"nctId":"NCT00936858","phase":"PHASE2","title":"RAD001 for Patients With Radioiodine Refractory Thyroid Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-07","conditions":"Thyroid Cancer","enrollment":50},{"nctId":"NCT03525834","phase":"PHASE4","title":"Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-09","conditions":"Renal Angiomyolipoma","enrollment":40},{"nctId":"NCT01524783","phase":"PHASE3","title":"Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03-30","conditions":"Advanced NET of GI Origin, Advanced NET of Lung Origin, Neuroendocrine Tumors","enrollment":302},{"nctId":"NCT01275222","phase":"PHASE1, PHASE2","title":"Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-11-13","conditions":"Gastrointestinal Stromal Tumors","enrollment":117},{"nctId":"NCT02137239","phase":"PHASE2","title":"Regimen Optimization Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT01789281","phase":"PHASE4","title":"Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05-14","conditions":"Neoplasms","enrollment":34},{"nctId":"NCT00702052","phase":"PHASE2","title":"Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-08-22","conditions":"Lymphoma, Mantle- Cell","enrollment":58},{"nctId":"NCT02732119","phase":"PHASE1, PHASE2","title":"Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-14","conditions":"Breast Cancer","enrollment":104},{"nctId":"NCT04867720","phase":"PHASE4","title":"Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-03-16","conditions":"Liver Transplant","enrollment":112},{"nctId":"NCT01865747","phase":"PHASE3","title":"A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Exelixis","startDate":"2013-06","conditions":"Renal Cell Carcinoma","enrollment":658},{"nctId":"NCT01857193","phase":"PHASE1","title":"Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09-06","conditions":"Breast Cancer","enrollment":132},{"nctId":"NCT01929642","phase":"PHASE2","title":"Rapalogues for Autism Phenotype in TSC: A Feasibility Study","status":"COMPLETED","sponsor":"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.","startDate":"2013-07","conditions":"Tuberous Sclerosis Complex, Self-injury, Autism","enrollment":3},{"nctId":"NCT01231659","phase":"PHASE2","title":"Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08-09","conditions":"Postmenopausal Women, Locally Advanced Metastatic Breast Cancer, Metastatic Breast Cancer","enrollment":72},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241},{"nctId":"NCT01783444","phase":"PHASE2","title":"A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-26","conditions":"Breast Cancer","enrollment":309},{"nctId":"NCT00827359","phase":"PHASE2","title":"Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2009-03","conditions":"Renal Cell Carcinoma, Renal Cancer","enrollment":25},{"nctId":"NCT03095040","phase":"PHASE3","title":"CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"AnewPharma","startDate":"2016-12-16","conditions":"Renal Cell Cancer Metastatic","enrollment":390},{"nctId":"NCT01482156","phase":"PHASE1","title":"Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-01","conditions":"Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma","enrollment":46},{"nctId":"NCT00466466","phase":"PHASE1","title":"Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-04","conditions":"Small-Cell Lung Cancer","enrollment":20},{"nctId":"NCT00434174","phase":"PHASE1","title":"Safety of Everolimus and Pemetrexed in Lung Cancer Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Non Small Cell Lung Cancer","enrollment":48},{"nctId":"NCT02511639","phase":"PHASE3","title":"Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2014-07-30","conditions":"Breast Cancer Metastatic","enrollment":110},{"nctId":"NCT02900716","phase":"PHASE1","title":"Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas","status":"COMPLETED","sponsor":"Zhejiang DTRM Biopharma","startDate":"2016-09","conditions":"Chronic Lymphocytic Leukemia, B-Cell Lymphoma","enrollment":48},{"nctId":"NCT01059318","phase":"PHASE2","title":"A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-01","conditions":"Lymphangioleiomyomatosis","enrollment":24},{"nctId":"NCT02113800","phase":"PHASE2","title":"Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2015-08","conditions":"Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3","enrollment":40},{"nctId":"NCT04471441","phase":"PHASE4","title":"Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-06-30","conditions":"Liver Transplant","enrollment":150},{"nctId":"NCT01627067","phase":"PHASE2","title":"Exemestane-RAD001-Metformin","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-09","conditions":"Breast Cancer","enrollment":23},{"nctId":"NCT01596140","phase":"PHASE1","title":"Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-12-18","conditions":"Advanced Cancer, Solid Tumor","enrollment":27},{"nctId":"NCT02017860","phase":"PHASE2","title":"Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-01-16","conditions":"Neoplasms","enrollment":4},{"nctId":"NCT03176238","phase":"PHASE3","title":"Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-29","conditions":"Post Menopausal Breast Cancer","enrollment":235},{"nctId":"NCT01158651","phase":"PHASE2","title":"Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2010-07-10","conditions":"Glioma","enrollment":23},{"nctId":"NCT01248403","phase":"PHASE3","title":"A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2011-10","conditions":"Advanced Gastric Cancer, Esophagogastric Junction Cancer","enrollment":300},{"nctId":"NCT01743560","phase":"PHASE4","title":"An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01-31","conditions":"Oestrogen Receptor Positive Advanced Breast Cancer","enrollment":52},{"nctId":"NCT01551212","phase":"PHASE4","title":"Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05-24","conditions":"Liver Transplantation","enrollment":339},{"nctId":"NCT00419159","phase":"PHASE2","title":"Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Colorectal Cancer","enrollment":199},{"nctId":"NCT00767819","phase":"PHASE2","title":"Treatment of Patients With RAD001 With Progressive Sarcoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-03-31","conditions":"Progressive Sarcoma","enrollment":71},{"nctId":"NCT01661283","phase":"PHASE2","title":"SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors","status":"COMPLETED","sponsor":"Sarcoma Alliance for Research through Collaboration","startDate":"2012-09","conditions":"Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma","enrollment":25},{"nctId":"NCT02970630","phase":"PHASE2","title":"Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-01","conditions":"Kidney Transplantation","enrollment":28},{"nctId":"NCT02115113","phase":"PHASE3","title":"REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-28","conditions":"Liver Transplantation","enrollment":78},{"nctId":"NCT00968253","phase":"PHASE1, PHASE2","title":"RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-11","conditions":"Leukemia, Acute Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT01115803","phase":"PHASE1","title":"A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2010-03","conditions":"Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma","enrollment":29},{"nctId":"NCT00688623","phase":"PHASE2","title":"RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06-24","conditions":"Advanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma, Neuroendocrine","enrollment":73},{"nctId":"NCT00876395","phase":"PHASE3","title":"Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09-10","conditions":"Breast Cancer","enrollment":719},{"nctId":"NCT01305941","phase":"PHASE2","title":"A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2011-09","conditions":"HER-2 Positive Breast Cancer","enrollment":32}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"ABDOMINAL PAIN"},{"count":3,"reaction":"RENAL IMPAIRMENT"},{"count":2,"reaction":"ACUTE KIDNEY INJURY"},{"count":2,"reaction":"CONCOMITANT DISEASE PROGRESSION"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"PRODUCT USE ISSUE"},{"count":2,"reaction":"STOMATITIS"},{"count":1,"reaction":"ABDOMINAL ABSCESS"},{"count":1,"reaction":"ALTERED STATE OF CONSCIOUSNESS"},{"count":1,"reaction":"ANGIOEDEMA"}],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Everolimus Tablets","genericName":"Everolimus Tablets","companyName":"Shandong Suncadia Medicine Co., Ltd.","companyId":"shandong-suncadia-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation. Used for Advanced renal cell carcinoma, Breast cancer (hormone receptor-positive, HER2-negative), Pancreatic neuroendocrine tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}